Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, has told DirectorsTalk about
Amgen Inc (NASDAQ:AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first
Ali Mortazavi Chief Executive of Silence Therapeutics commented: “Silence has been fully focused on progressing a high conviction IND/CTA filing to spearhead the platform potential of RNA therapeutics. Central to this have been the key senior
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics Plc LON:SLN , commented: “We are delighted to have attracted such high calibre and experienced individuals to join our team. We plan to
Silence Therapeutics plc, AIM: SLN a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, has told DirectorsTalk that on
Ali Mortazavi, CEO of Silence Therapeutics PLC (LON:SLN), said: “The final data confirms the close relationship between PFS and OS as seen in most pancreatic cancer trials as well as the
Silence Therapeutics plc, AIM: SLN a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, has told DirectorsTalk about the
Silence Therapeutics plc, AIM: SLN a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, has informed DirectorsTalk of the
What is interesting about the recent charting position at Silence Therapeutics (LON:SLN) is the way that even before the latest gap to the upside it appeared that the shares were
One of the simplest and more effective charting rules is that when a stock or market is below the 200 day moving average we can regard it as being bearish,
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
